What is Editas Medicine?
Editas Medicine is a genome editing company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Genome editing company
- Headquarters
- Cambridge, United States
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: EDIT
What is Editas Medicine?
Editas Medicine is a genome editing company company headquartered in Cambridge, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Editas Medicine is a genome editing company company headquartered in Cambridge, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Editas Medicine should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Editas Medicine offer?
Editas Medicine's profile centers on Genome editing, CRISPR medicines, Clinical development, Rare diseases.
- Genome editing· Genome editing company
- CRISPR medicines· Genome editing company
- Clinical development· Genome editing company
- Rare diseases· Genome editing company
- Platform technology· Genome editing company
- R&D· Genome editing company
How does Editas Medicine make money?
Editas Medicine makes money through commercial activity tied to genome editing company.
Editas Medicine monetizes through the model common to genome editing company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Editas Medicine?
Editas Medicine's named executives should be verified on the official leadership or investor-relations page before outreach.
- Editas Medicine executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Editas Medicine finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Editas Medicine operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Editas Medicine's leadership?
Editas Medicine should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.editasmedicine.com- Editas Medicine investor relationsInvestor relations / corporate contactcontact via https://www.editasmedicine.com
- Editas Medicine sales or partnershipsCommercial contact routecontact via https://www.editasmedicine.com
- Editas Medicine media relationsMedia or communications contact routecontact via https://www.editasmedicine.com
How is Editas Medicine funded?
Editas Medicine's current status is Public company; Nasdaq: EDIT.
Editas Medicine's capital profile is best understood through its current public-company status: Public company; Nasdaq: EDIT. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Editas Medicine get here?
Editas Medicine's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingEditas Medicine is foundedThe company begins building in genome editing company.
- Scale-upCommercial footprint expandsEditas Medicine broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: EDITPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Editas Medicine's competitors?
Editas Medicine competes with larger incumbents and focused specialists in genome editing company.
Editas Medicine — frequently asked questions
